#GenkyDrugStores

For January 2026, total store sales were 105.7% YoY, existing stores 98.6%, with one new store opened, bringing the total number of stores to 500.

For the second quarter of the fiscal year ending June 2026, net sales were JPY 109,261 million (10.6% YoY increase), operating income was JPY 5,717 million (24.4% YoY increase), and net income attributable to owners of parent was JPY 4,020 million (23.0% YoY increase).

For FY2026 Q2, net sales amounted to 53.218 billion yen, a 9.3% increase year-over-year, operating income was 2.801 billion yen, up 20.6%, and the full-year earnings guidance has been revised upward to sales of 221.2 billion yen and operating income of 11.05 billion yen.

For the fiscal year ending June 2026, net sales were JPY 221.2 billion, up 10.2% YoY; operating income was JPY 11.05 billion, up 14.45% YoY; and net income was JPY 7.85 billion, up 11.15% YoY.

Operating income for the second quarter of the fiscal year ending June 2026 has been revised upward from 5,270 million yen to 5,717 million yen, an increase of 8.5%. Full-year operating income has also been revised upward from 10,500 million yen to 11,050 million yen, a 5.2% increase.

In the December monthly update for the fiscal year ending June 2026, total store sales increased 110.6% year-over-year (YoY), and same-store sales grew 103.3% YoY, showing steady trends. Both customer count and average spend per customer exceeded the previous year, while the number of stores expanded to 499.